Arvind Remedies Peer Comparison

NSE: ARVINDREM | BSE: 531823

₹4.70

₹-0.24 (-4.86%)

As on 13-Jun-2016IST

Market cap

₹32 Cr

Revenue (TTM)

₹12 Cr

P/E Ratio

P/B Ratio

-0.2

Div. Yield

0 %

Edit

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	32	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	12	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-137.36	414.00	288.22	-371.81	387.35
Net Margin (%)	-1,121.27	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	-0.20	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	962.68	4,830.36	41.58	--	76.11
Total Income	963.22	4,914.64	41.73	--	76.68
Total Expenditure	781.32	3,850.53	30.00	--	69.99
EBITDA	181.36	979.83	11.59	--	6.12
Depreciation	14.34	139.92	3.35	--	0.80
EBIT	167.03	839.91	8.24	--	5.32
Interest	78.51	83.35	2.34	--	1.58
Other Income	0.54	84.28	0.14	--	0.56
Exceptional Items	--	49.83	--	--	--
Profit before Tax	89.05	890.67	6.04	--	4.31
Provision for Tax	28.69	47.88	1.54	--	1.44
Profit after Tax	60.36	842.79	4.50	--	2.86

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	283.06	3,581.47	44.83	--	10.77
Minority Interest	4.85	136.17	--	--	--
Non-Current Liabilities	288.00	1,161.18	10.36	--	1.29
Current Liabilities	547.46	1,743.20	21.34	--	26.33
Total Liabilities	1,123.36	6,622.02	76.53	--	38.71

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	433.26	3,266.10	51.75	--	7.38
Current Assets	690.11	3,355.92	24.78	--	31.01
Total Assets	1,123.36	6,622.02	76.53	--	38.71
Total Debt*	640.97	1,906.08	21.09	--	12.17
Net Current Assets	142.65	1,612.72	3.44	--	4.68
Contingent Liabilities	1.20	267.40	4.70	--	--

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-65.08	1,476.29	6.29	--	-0.21
Cash Flow from Investing Activities	-24.64	-851.62	-5.46	--	-2.00
Cash from Financing Activities	71.24	-601.32	-0.58	--	2.17
Net Cash Inflow / Outflow	-18.48	23.35	0.25	--	-0.04

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	20.48	18.98	13.38	--	29.97
ROE (%)	26.81	30.04	19.08	--	30.26
ROA (%)	6.07	13.36	6.16	--	8.85
EBIT Margin (%)	18.90	22.03	28.21	--	8.78
Net Margin (%)	6.27	17.15	10.78	--	3.74
Cash Profit Margin (%)	7.33	20.32	18.86	--	4.81

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	36.34	-13.89	12.11	--	37.10
EBIT Growth (%)	28.76	-49.66	21.82	--	30.95
Net Profit Growth (%)	34.25	-46.64	58.36	--	39.55
EPS Growth (%)	-4.56	-56.04	58.36	--	39.55
Book Value Growth (%)	57.80	36.37	21.09	--	32.03

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	5.03	6.59	0.00	--	0.00
Price / Book Value	1.07	1.55	0.00	--	0.00
Dividend Yield (%)	1.85	2.19	--	--	--
EV/EBITDA	5.11	5.73	3.52	--	2.02
Market Cap (₹ Cr)	293.96	5,016.58	0.00	--	0.00

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	2.33	0.54	0.47	--	1.13
Short term debt to equity ratio	1.22	0.06	0.23	--	0.84
Current Ratio	1.26	1.93	1.16	--	1.18
Quick Ratio	0.90	1.36	1.11	--	0.75
Interest Coverage	2.13	11.69	3.58	--	3.73

	Arvind Remedies	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	36.39	9.96	33.85	--	17.81
Asset Turnover	1.02	0.77	0.57	--	2.35
Receivable days	109.13	54.33	106.93	--	58.46
Inventory Days	58.18	77.43	10.49	--	41.85
Payable days	41.26	120.43	213.33	--	91.25
Cash Conversion Cycle	126.04	11.32	-95.91	--	9.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.